within note preview select specialti pharmaceut compani
believ key discuss point upcom earn report
believ allergan easili meet street revenu
earn expect specif model revenu earn
quarter though estim factor gener restasi arriv quarter
occur make street target like accur anticip
adjust cash gener roughli place oper well track
exceed manag guid full year bottom-lin
posit momentum continu
quarterli specif hard argu oper perform
core durabl franchis anyth solid number reason
believ allergan continu put rel strong result approxim
allergan busi medic aesthet cash pay busi
bolster growth botox coolsculpt juvederm given
season medic aesthet believ remain solid escal
bolster even aggress dtc campaign specif
botox juvederm allergan undertaken past none
factor appear strengthen ex-u trend line botox migrain
still appear suffer aimovig launch unlik suffer
introduct ajovi emgal given product suppli
essenti cost manag care pressur payor push back allow
clinician continu util botox unencumb believ set-up could
persist least next month market effort organ
appear bring addit patients/attent categori commentari
much line recent clinician check indic
slow botox util current forecast recal allergan
previous guid growth botox use migrain spastic
overact bladder busi see reason prove accur
vraylar dtc advertis initi februari success new patient start
prescript volum strong trend
bipolar schizophrenia label vraylar run rate nearli
snda bipolar depress submit fda potenti addit
indic bolster believ ultim
long-dur franchis process divest infecti diseas women
remain on-going track manag like continu stress
sell profit corpor margin busi unless
receiv fair valu although obviou statement believ manag
reinforc even greater commit secur right price given cash gener
franchis durabl therefor exit unless fair
valuat sharehold receiv howev would note manag
alreadi rel quietli sold medic dermatolog portfolio almiral
well divestit rhofad aclari view continu strateg narrow
pleas see page report import disclosur
observ last quarter believ guidanc anoth modest increas
allergan key compon underli portfolio still rel earli
growth phase remain sustain remark given length
time key botox franchis market also believ develop
program easili dismiss street sentiment improv
await phase disclosur rapastinel well file ubrogep
allergan acut use oral cgrp migrain restasi assum gener
street model leav bystol revenu subject exclus loss
next year alreadi well factor well understood
modest pipelin success model continu indic allergan prove
durabl revenu earn growth compani next decad least
mean revenu earn expect appear properli set
continu stabl perform oper leverag continu
share compani good cash gener pay
debt make share repurchas commit dividend increas variou
develop asset set report late stage data file approv next
month durabl growth portfolio post essenti holi grail
normal make stock work clearli believ nice set-up
exit enter
anticip shire meet street expect revenu
earn project metric respect
combin takeda right garner much attent
underli busi continu perform expect oper cash gener
debt pay thesi remain much intact continu estim shire
exit approxim leverag would stress durabl
compon shire busi immunolog well variou
orphan franchis continu outperform complement
still strong hemophilia inhibitor perform valid belief fear
conserv model would far exceed actual realiti competit launch
although fundament pharmaceut analyst merger arbitrag expert
given strong core perform believ still floor valuat
would encourag play spread ad shpg ahead like takeda close
believ valuat protect level shire share trade
roughli discount takeda offer price current given current
recal call manag reiter full year product guidanc
given perform impli revenu roughli
manag indic perform heavili weight
expect impact sequenti cinryze/firazyr revenu decreas roughli
q/q due de-stock time shipment believ
street revenu target appropri reflect like impact
import metric recal experienc ig sale growth
driven increas demand also includ time intern order
forecast modest expect line becom critic off-set hemophilia
anticip on-going favor commentari manag addit
anticip detail discuss covington georgia plasma manufactur
site approv late immedi began commerci shipment
given sale oncolog segment servier close august
believ leverag figur look even favor
guidanc current revenu y/i growth anticip
earn per share believ reiter competit
implic hemlibra haegarda continu off-set
immunolog vyvans xiidra takhzyro launch other bottom line
oper de-lever remain much track
expect meet street revenu expect earn
expect current model revenu y/i q/q
earn y/i q/q essenti in-lin street
current valuat roughli cash debt
net debt roughli simpli assum current cash gener
anticip growth core portfolio would gener roughli cash
xyrem initi limit gener introduct januari would mean
current cash gener debt would elimin residu cash would equat
nearli current market capit addit point
say limit gener introduct exclus holder hikma anticip
launch author gener believ carri signific royalti back
two author settlement lupin even limit
suppli hikma also like signific royalti mean
januari point second tier entrant januari
like still hold least half xyrem franchis assum although
complet possibl franchis would fulli convert low-sodium
once-nightli formul time standard gener introduct state
clearli year solid cash gener ahead still possibl complet
preserv xyrem contribut significantli longer current assum
believ posit busi develop perspect
uniqu nich orphan oncolog hematolog potenti target companies/product
categori often small focus patient popul sale
could hundr million often one billion typic
larger oncology-bas pharmaceut biotechnolog compani tend focu yet
potenti return invest given durabl asset target
commerci effort substanti success execut addit
diversif durabl profit orphan oncolog hematolog
therapeut categori would like caus potenti re-rat valuation/multipl
follow rare wit success evolut specialti pharmaceut
biopharma believ occur still underappreci could
recal xyrem experienc y/i bottl growth y/i patient
volum growth appear unbrand advertis campaign
remain on-going appear work intend steadili increas rate
narcolepsi diagnosi full year xyrem revenu guidanc rais
repres growth y/i impli second half sale
model xyrem sale
area focu on-going vyxeo launch recal call manag
reduc full year vyxeo revenu guidanc given
result guidanc figur impli model vyxeo
sale believ figur reach long term growth vyxeo
expect gener larg part expans indic geographi
near-term perform still-launch vyxeo expect gener
increas sale forc implement juli continu educ
clinic benefit profil vyxeo aml versu target therapi also
current launch new technolog add-on payment approv
earli august help defray cost vyxeo hospit medicar
patient also expect addit commentari impend launch european
countri follow august chmp approv recal launch occur stage
first wave launch includ netherland germani franc
nordic countri countri payment landscap work
process individu gradual build european vyxeo
erwinaz remain bit controversi due on-going manufactur issu
partner model importantli appear manag
guidanc account continu on-going suppli issu given top full year
guidanc would impli flat sale versu recent updat suppli
situat via erwinazesuppli com indic interrupt begin octob
could impact unlik impact publish
erwinazesuppli com indic expect resum shipment erwinaz
week novemb earliest could mean resolut
abil still meet target suppli issu essenti
last year although street made awar fluctuat
believ point fairli standard fairli well understood meaning
potenti caus minor q/q fluctuations/frustr well
model fluctuat impact overal valu franchis
pipelin continu progress expect increment updat
solriamfetol launch prepared phase trial
recal solriamfetol wake-promot agent decemb pdufa date follow
expect approv schedul complet like late first quarter
launch follow thereaft sale forc expans expect first quarter
next year though pre-launch prepar underway time believ
solriamfetol phase data show best-in-class wake promot agent
physician survey work lead us believ solriamfetol could becom like
long durat product approv solriamfetol would nice complement on-going
lower sodium xyrem formul requir placebo-
control phase trial measur safeti efficaci trial enrol latest
guidanc spring top line disclosur believ program nice on-track
await updat call reflect meaning preserv xyrem
beyond exclus window anyth posit formul once-nightli
would nice addit
expect horizon meet street expect revenu
earn follow net sale guidanc revenu
impli model revenu y/i
primari care sale segment expect remain flat q/q krystexxa sale
anticip continu ramp model earn essenti in-lin
street figur look achiev
believ strong momentum horizon continu recal follow
earn report revenu guidanc maintain ebitda rang
improv previou would note
manag increas guidanc fulli incorpor assum y/
increas combin oper spend horizon ramp commerci invest
support krystexxa increas spend support on-going phase
teprotumumab program continu believ spend encourag
given specif toward set stage futur growth krystexxa remain
dramat under-penetr target market well teprotumumab
opportun believ could ultim believ leverag
invest becom significantli evid
believ street point fulli contempl
krystexxa achiev sale y/i base strong volum growth
model continu growth y/i believ prove
accur in-lin meet manag y/i revenu growth target
impli full year sale franchis appear nice on-track
core orphan busi gener roughli total revenu
continu de-emphasi legaci primari care busi importantli
stabil primari care product believ franchis might easier
exit investor view divis essenti strateg monetiz
asset longer core believ manag eventu abl secur
reason valuat nonetheless despit reduc relev overal horizon
stori believ investor pay attent line given histori therefor
perform remain somewhat import horizon guid primari care net
sale least franchis reach y/i
includ alway season weak gross net adjust
peak project sale y/i q/q per prescript
profit expect escal
call also expect addit commentari teprotumumab pre-launch
activ recent acceler due complet enrol pivot
phase optic trial ahead schedul top line data program due
file launch anticip horizon indic
belief teprotumumab potenti long durat product consult
feedback remain encourag remain encourag on-going transit
total horizon busi toward orphan acceler
believ like fall short street revenu expect
earn expect current estim revenu earn
recent result consensu led downward revis
guidanc given lack advair restasi approv date publish
believ good chanc previous revis revenu guidanc
could get narrow lower end rang
would correspondingli like lead narrow lower end
earn guidanc continu believ delay new
replac cycl caus increas pressur manag make addit
wealth destroy acquisit would continu avoid
despit lower revenu expect manag maintain cash flow
guidanc would stress level cash flow similar
record despit acquisit last
year addit ebitda via purchas
use observ via roughli acquir current market product
recent spent anoth acquir novarti tobi podhal
unsur total sale product roughli
undisclos product tobi acquir underscor strategi continu
take balanc sheet bolster specif net cash provid
oper activ make
adjust free cash flow guidanc forecast declin y/i
estim fairli indic true underli trend bad
larger pictur continu view roughli flat cash gener
last year guid year good marker health lack thereof
busi analysi see share repurchas line
alter believ long-term investor cash gener trend
troubl caus paus analyz health underli busi
fact like gener manufactur believ lack cash gener new
product introduct despit heavi spend caus question
full year result clearli impact advair fda decis follow
resubmiss label issu review fda
anticip take three month mid-juli resubmiss howev still await
fda decis recent indic expect immin
also await updat anticip gener restasi call
indic receiv product request minor clarif
respons alreadi submit await updat call
would also expect updat on-going issu stem form issu
earlier year morgantown manufactur facil result fda
observ mylan began implement restructur remedi program
facil reduc capac short term addit
manufactur restraint partner experienc limit abil
suppli epipen would expect updat on-going situat well
final look forward updat board director on-going assess
optim path forward compani recal august mylan board form
strateg review committe activ evalu wide rang altern unlock
true valu full strateg review unlik complet time would
expect commentari statu committe evalu discuss
possibl lbo given view asset believ entir unlik
expect teva meet street revenu expect revenu ep
consensu
call guidanc rais ep
free cash flow ep guidanc remain
remaind year model y/i q/q
gener revenu y/i q/q believ given lack
meaning copaxon competit teva abl produc anoth good
quarterli result howev discuss short-term relief believ
translat well long-term valu creation
view invest thesi doubt addit ceo kare
shultz upgrad cfo michael mcclellan provid meaning increas confid
could posit capabl strongli believ
make everi right decis possibl howev unfortun free cash flow remain
concern reach perform still includ retent
better expect amount copaxon revenu manag
rapidli reduc cost save reach year-end doubl
figur next year valuat alreadi reflect potenti posit
must confront realiti base busi uninterest hope relief
manag believ occur cgrp could prove pain costli
appropri factor pressur gener line
intern well expect continu copaxon declin off-set fairli
dramat expens reduct dcf indic total asset worth
roughli per share would note analysi includ assumpt
teva cgrp ajovi abl reach peak sale significantli
lower assumpt return back per share current price target
analyz model multipl differ way even small move
trajectori gener divis realli dont meaning impact
valuat long essenti durabl current cost structur
clearli could alter valuat would ajovi materi larger
model convers materi smaller given continu
believ disadvantag dose profil compar competitor believ
product go prove bit disappoint ajovi launch like
greatest area focu call recal product approv mid-septemb
launch immedi product suppli pre-fil syring instead
auto-injector view dose profil disadvantag express script
recent indic includ competitor lilli emgal
aimovig formulari exclud ajovi teva favor howev quarterli
dose label veru competitor monthli consult indic
needl smaller less pain auto injector help mitig product
profil manag discuss launch strategi commentari express
script exclus inform investor view eventu potenti
product discuss critic forward valuat given
appear extrem competit price environ lilli seem
content give product away free forese futur littl
expect ajovi becom meaning contributor
remaind core oper manag stress debt pay-down
prioriti compani current hold slightli net debt ebitda manag
indic current target leverag ratio expect abl
achiev approxim year second quarter paid
place net debt current expect similar reduct
copaxon retain far market share mani fear
momenta/sandoz gener combin captur less total
prescript new prescript accord iqvia market
share remain steadi price market greatli diminish consequ
aggress price tactic model total copaxon revenu
third quarter y/i q/q although could prove conserv
teva austedo launch progress well show q/q growth
sale call manag indic see encourag trend
patient volum propel sale growth model continu growth
q/q though could prove conserv
expect aeri meet street revenu expect rhopressa
rx trend line trend nice upward launch indic proceed
well hoped/expect importantli believ aeri abl
reiter net sale guidanc
specif would note point launch mani metric
refills/rx bottles/rx net realiz price/rx yet normal shown
slide appear averag prescript trend toward
suppli mean valu per prescript could higher mani anticip
inde week octob total amount bottl
dispens order reflect multipl approxim
bottl per monthli model per iqvia-measur prescript
premium per bottl realiz prescript util
higher prescript valu alreadi report juli august septemb result
would yield revenu easili reach street consensu figur
addit commerci coverag ad patient visit clinician
fall patient receiv sampl convert pay custom
anticip prescript figur continu acceler anticip
updat medicar part coverag octob cover prefer
tier whether aeri abl increas number commerci live current
impress stage launch and/or new
convers tier tier commerci coverag tier tier
octob nonetheless earli figur encourag nice line
expect importantli remain encourag continu solid
clinician feedback critic stage launch
continu believ quarterli perform could fluctuat
fairli littl relev await cch cellulit data critic
aspect endo stori point nonetheless recent oper
encourag result manag increas previou revenu
guidanc new rang previous earn per
share clearli appear consist
oper believ result view favor
encourag manag abil stabil variou busi
howev current level cash flow flat y/i versu current
level net debt liabil known unknown believ
valuat fair perspect dcf indic per share without cch
cellulit includ given never receiv strong opinion
aesthet consult phase cch program set disclos data later
year posit need lean closer core valu hope
unfortun littl faith oper
quarter quarter believ addit liabil reserv may inde necessari
specif testosteron opioid reason remain bit cautiou
clearli view could materi chang cch result favor
expect supernu meet beat street revenu expect
earn expect given continu posit recent prescript trend
trokendi expect investor focu remain impact cgrp introduct
believ given rel small size product larg indic
trokendi abl continu maintain solid nich migrain prevent
paradigm nonetheless await manag detail feedback
oper follow strong first half manag increas low end
previou product sale guidanc
oper earn guidanc increas howev
septemb supernu acquir biscayn neurotherapeut lead asset novel
synthet form huperzin potent acetyl cholinesteras inhibitor
pharmacolog activ condit epilepsi specif program
phase studi receiv orphan drug design fda
treatment dravet syndrom sever form childhood epilepsi addit
manag indic would increas take oper earn
guidanc back year impact revenu
first half revenu guidanc impli believ
easili achiev particularli given consist season stronger model
sale y/i flat q/q expect come
also expect updat expect time enrol statu on-going
phase trial non-stimul adhd impuls
aggress adhd first four pivot phase trial expect
produc data year-end enrol remain three trial
call two pivot phase trial reach
enrol respect call oxtellar xr phase program bipolar
disord also expect begin though manag priorit
believ share higher
expect neo meet street revenu expect though
remain encourag adzeni xr-odt prescript continu upward trend
experienc nice inflect enter back-to-school season strong prescript
growth observ august septemb back school season acceler
total prescript volum quarter suggest adzeni produc roughli
sale cotempla launch also solid prescript
trend easili outpac adzeni level similar stage launch due already-
establish sale forc faster payor coverag total prescript volum quarter
suggest cotempla xr-odt produc roughli sale could
inventori trade build could boost result importantli expect net sale
per prescript adzeni cotempla continu rise manag
indic prescript price grow adzeni nearli
cotempla end versu respect
bottom-lin believ patienc reward manag
establish product continu work broaden coverag
simpli take time resili current valuat believ patienc
expect meet street revenu expect
imvexxi paid prescript trade fill like exceed consensu
revenu predict latest disclosur paid prescript august
